Publication title: “Oral Blarcamesine Phase IIb/III Trial Confirms Identified Precision Medicine Patient Population – Significant Broad Clinical and Quality of Life Improvements for Early Alzheimer’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback